Detalles de la búsqueda
1.
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer.
Ann Oncol
; 34(9): 783-795, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37302750
2.
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study.
Ann Oncol
; 30(6): 921-926, 2019 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30778520
3.
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials.
Breast Cancer Res Treat
; 163(2): 295-302, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28289852
4.
Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors.
Invest New Drugs
; 35(6): 766-772, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28317088
5.
Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab.
Br J Cancer
; 111(1): 25-32, 2014 Jul 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-24892446
6.
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials.
Breast Cancer Res Treat
; 163(3): 637, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28374322
7.
Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival.
ESMO Open
; 7(2): 100409, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35227965
8.
Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials.
ESMO Open
; 7(2): 100433, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35276440
9.
A systematic review of contemporary phase I trials in patients with lymphoma.
Crit Rev Oncol Hematol
; 180: 103860, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36265547
10.
Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer.
NPJ Precis Oncol
; 5(1): 23, 2021 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-33742063
11.
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study.
ESMO Open
; 6(2): 100099, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33819752
12.
Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all?
Cancer Treat Rev
; 60: 100-108, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-28942029
13.
Erratum to 'Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival': [ESMO Open Volume 7, Issue 2, April 2022, 100409].
ESMO Open
; 7(3): 100472, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35398607
14.
Fat grafting for breast cancer patients: From basic science to clinical studies.
Eur J Surg Oncol
; 42(8): 1088-102, 2016 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-27265042
Resultados
1 -
14
de 14
1
Próxima >
>>